Estella M Alonso1, Simon P Horslen2, Edward M Behrens3, Edward Doo4. 1. Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 2. Department of Pediatrics at the University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA. 3. Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA. 4. Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Abstract
Pediatric acute liver failure (PALF) is a potentially devastating condition that occurs in previously healthy children of all ages and frequently leads to a rapid clinical deterioration. An identified cause for liver injury is lacking in approximately 30% of cases. Children with undetermined diagnosis have lower spontaneous survival and higher rates of transplantation and death than other diagnostic groups. A single-day workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases brought together clinicians and basic scientists to integrate aligned research findings and develop a foundation for new mechanistic studies and future treatment trials. The clinical phenotype of indeterminate PALF shares important similarities to the hyperinflammatory state characteristic of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). A failure of cytotoxic T cells to limit or contract inflammatory responses may propagate injury and lead to a local and systemic milieu that does not support normal hepatic regeneration. Evidence was presented that bone marrow (BM)-derived Sinusoidal endothelial cell PROgenitor Cells (sprocs) play a vital role in hepatic regeneration. Overwhelming systemic inflammatory responses may suppress mobilization of BM sprocs and dampen hepatic recovery. CONCLUSION: Experience gained through treatment trials of HLH and MAS in childhood may inform study design for therapy of PALF. Successful approaches to limiting neuroinflammation through reduction of systemic inflammation and standardized neuroprotection protocols that limit glial injury could significantly improve intact survival. Finally, given that PALF is a rare disease, investigative efforts must include broad multicenter collaboration and careful stewardship of biorepository specimens. (Hepatology 2017;65:1026-1037).
Pediatric acute liver failure (PALF) is a potentially devastating condition that occurs in previously healthy children of all ages and frequently leads to a rapid clinical deterioration. An identified cause for liver injury is lacking in approximately 30% of cases. Children with undetermined diagnosis have lower spontaneous survival and higher rates of transplantation and death than other diagnostic groups. A single-day workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases brought together clinicians and basic scientists to integrate aligned research findings and develop a foundation for new mechanistic studies and future treatment trials. The clinical phenotype of indeterminate PALF shares important similarities to the hyperinflammatory state characteristic of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). A failure of cytotoxic T cells to limit or contract inflammatory responses may propagate injury and lead to a local and systemic milieu that does not support normal hepatic regeneration. Evidence was presented that bone marrow (BM)-derived Sinusoidal endothelial cell PROgenitor Cells (sprocs) play a vital role in hepatic regeneration. Overwhelming systemic inflammatory responses may suppress mobilization of BM sprocs and dampen hepatic recovery. CONCLUSION: Experience gained through treatment trials of HLH and MAS in childhood may inform study design for therapy of PALF. Successful approaches to limiting neuroinflammation through reduction of systemic inflammation and standardized neuroprotection protocols that limit glial injury could significantly improve intact survival. Finally, given that PALF is a rare disease, investigative efforts must include broad multicenter collaboration and careful stewardship of biorepository specimens. (Hepatology 2017;65:1026-1037).
Authors: Alexei A Grom; Norman T Ilowite; Virginia Pascual; Hermine I Brunner; Alberto Martini; Daniel Lovell; Nicolino Ruperto; Karolynn Leon; Karine Lheritier; Ken Abrams Journal: Arthritis Rheumatol Date: 2016-01 Impact factor: 10.995
Authors: Julia E Rood; Sheila Rao; Michele Paessler; Portia A Kreiger; Niansheng Chu; Erietta Stelekati; E John Wherry; Edward M Behrens Journal: Blood Date: 2015-10-30 Impact factor: 22.113
Authors: Scott W Canna; Charlotte Girard; Louise Malle; Adriana de Jesus; Neil Romberg; Judith Kelsen; Lea F Surrey; Pierre Russo; Andrew Sleight; Eduardo Schiffrin; Cem Gabay; Raphaela Goldbach-Mansky; Edward M Behrens Journal: J Allergy Clin Immunol Date: 2016-11-19 Impact factor: 10.793
Authors: Ashish Singhal; Saraschand Vadlamudi; Kenneth Stokes; Francis P Cassidy; Ayumi Corn; Stan S Shrago; Harlan I Wright; Vivek Kohli Journal: Transpl Int Date: 2012-04-05 Impact factor: 3.782
Authors: David E Kleiner; Naga P Chalasani; William M Lee; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Paul H Hayashi; Timothy J Davern; Victor Navarro; Rajender Reddy; Jayant A Talwalkar; Andrew Stolz; Jiezhun Gu; Huiman Barnhart; Jay H Hoofnagle Journal: Hepatology Date: 2013-12-18 Impact factor: 17.425
Authors: Michael R Narkewicz; Simon Horslen; Regina M Hardison; Benjamin L Shneider; Norberto Rodriguez-Baez; Estella M Alonso; Vicky L Ng; Mike A Leonis; Kathleen M Loomes; David A Rudnick; Philip Rosenthal; Rene Romero; Girish C Subbarao; Ruosha Li; Steven H Belle; Robert H Squires Journal: Clin Gastroenterol Hepatol Date: 2018-04-30 Impact factor: 11.382
Authors: James E Squires; David A Rudnick; Regina M Hardison; Simon Horslen; Vicky L Ng; Estella M Alonso; Steven H Belle; Robert H Squires Journal: Hepatology Date: 2018-11-01 Impact factor: 17.425
Authors: Mohit Kehar; Noelle H Ebel; Vicky L Ng; Jairo Eduardo Rivera Baquero; Daniel H Leung; Voytek Slowik; Nadia Ovchinsky; Amit A Shah; Ronen Arnon; Tamir Miloh; Nitika Gupta; Saeed Mohammad; Debora Kogan-Liberman; James E Squires; Maria Camila Sanchez; Amber Hildreth; Linda Book; Christopher Chu; Leina Alrabadi; Ruba Azzam; Bhavika Chepuri; Scott Elisofon; Rachel Falik; Lisa Gallagher; Howard Kader; Douglas Mogul; Quais Mujawar; Shweta S Namjoshi; Pamela L Valentino; Bernadette Vitola; Nadia Waheed; Ming-Hua Zheng; Steven Lobritto; Mercedes Martinez Journal: J Pediatr Gastroenterol Nutr Date: 2021-06-01 Impact factor: 2.839
Authors: Ruben Zamora; Derek Barclay; Jinling Yin; Estella M Alonso; Mike A Leonis; Qi Mi; Timothy R Billiar; Richard L Simmons; Robert H Squires; Yoram Vodovotz Journal: Sci Rep Date: 2019-04-12 Impact factor: 4.379
Authors: Elizabeth C Verna; Marina Serper; Jaime Chu; Kathleen Corey; Oren K Fix; Karen Hoyt; Kimberly A Page; Rohit Loomba; Ming Li; Gregory T Everson; Michael W Fried; Guadalupe Garcia-Tsao; Norah Terrault; Anna S Lok; Raymond T Chung; K Rajender Reddy Journal: Hepatology Date: 2020-11 Impact factor: 17.298